Achillion Pharmaceuticals, Inc. is a science-driven, patient-focused company. Our mission is to discover and advance potentially life-saving medicines for patients with rare diseases, such as C3G and PNH. We are committed to delivering on the promise of complement-based therapeutics, including our portfolio of factor D inhibitor compounds, as well as educating and supporting patients and their caregivers. Learn more about Achillion.
WeC3G Patient Support Initiative
C3G Patient-Focused Drug Development
For additional information on Achillion’s PNH clinical trials, please visit: